MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusEzetimibe for primary hypercholesterolemiaHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisIntensive glucose control versus conventional glucose control for type 1 diabetes mellitusHMG CoA reductase inhibitors (statins) for kidney transplant recipientsTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusStatins for the primary prevention of cardiovascular diseaseTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusStatins for the primary prevention of cardiovascular diseaseHMG CoA reductase inhibitors (statins) for kidney transplant recipientsHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisEzetimibe for primary hypercholesterolemiaOpening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular riskAre statins diabetogenic?Standards of medical care in diabetes--2012Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque developmentEffects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patientsUric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]Neurohumoral stimulation in type-2-diabetes as an emerging disease conceptThe need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]Statins research unfinished saga: desirability versus feasibilityThe case for low carbohydrate diets in diabetes managementComparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS studyFenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]Evidence-based prescribing of statins: a developing world perspective.Recent advances in managing and understanding diabetic nephropathy2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)Diabetes DyslipidemiaCardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?Lipid-lowering therapy: who can benefit?Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survivalModulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsClinical review: Screening for coronary artery disease in type 2 diabetes.A novel therapeutic effect of statins on nephrogenic diabetes insipidusTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.Glycemic control and cardiovascular disease: what's a doctor to do?How do we improve patient compliance and adherence to long-term statin therapy?Treatment of metabolic syndrome
P2860
Q22241786-3325B5AB-2F03-4BB5-BA30-A32B098E1D94Q24186667-C388488F-9B9B-42BA-8DF4-B7F4A478122CQ24187681-DCAC06C2-2148-4652-B024-CF0D1CEC80CDQ24194514-DA853C8A-9844-4416-9851-DABBD56B17D8Q24200376-083AF86A-DE7B-44E7-9F99-0F1EF1C7501AQ24200984-3E8D9BF4-D48D-4A0E-9F8F-5E3F67F5B29EQ24202505-1992EF00-1416-4935-BE64-08AA65408655Q24234813-6BE418E9-466A-47B8-8868-1275764D495DQ24236456-4326B116-7402-471B-A7DD-18C9433AF435Q24240283-2E9FF7DB-A30D-4437-9FA0-793DCDC15EB5Q24241098-67C62C31-8057-4540-9ABF-973BDDB483B9Q24241472-8D06E38C-60BD-4EA9-BB8C-8E429275A82DQ24244704-955F8E9A-96CA-4D1F-BFF0-CC9F5583CDE7Q24626884-3416F01A-582B-4D2E-A4AB-A381556D49AFQ24630205-114A6EA6-C5FD-4F2A-A9A8-8061580F9D2BQ24632533-E2B39714-B20C-4A58-BAB7-49F4376903C1Q24634492-575C2D2B-AE1B-41A8-B54B-1105CC1E342DQ24634840-AED495D6-C0EB-406D-8CFD-04BB3DB521C6Q24678615-A21B6F79-E89F-46D1-BC5E-248F1224BCC8Q24793837-B8B0B1C2-D608-4EE7-849B-586BFB440341Q24798310-403AB6FC-466E-4559-8014-E482391DFAE5Q24804541-644EB459-7B7B-4EB7-AA50-1EB807818818Q24811267-A6D2D0AC-9E15-4C4E-8CA3-F42C95F2E808Q24814561-5F5C0430-1369-47DD-98F3-B4F74A3FFF2DQ24814804-6B250BC1-0BA6-4B3B-9928-FEF49841902BQ24815913-76B8984C-199D-4DBC-B1AC-F836273BDBDBQ25255887-6B3AC653-2144-4E5C-9755-83C37FE9E4B3Q26745900-9960F452-FFFA-42F9-BCE9-1A9F4A147CF1Q26747559-6892874E-35D3-43E5-A3AE-7CA16B5FB436Q26750905-43730059-9D58-4F4A-BCB9-5BB20C6F146FQ26752255-7A6D5504-7BC7-4306-AE57-80B9534BE53EQ26827432-C71C1660-2ADA-4424-984F-02986D54B5BDQ26827620-076FFB40-1E85-4727-B148-6212AAFA3017Q26829098-6479E378-4F6B-4853-952E-89264F21D554Q26860716-47BA475F-7990-4C9B-8927-E8A0DA89B931Q27005638-76EBE7D0-86CE-4A6F-9B61-D9DAE73032D0Q27007027-39C8B3A3-8957-4BDE-B5D1-115020492D74Q27024469-2CE5F212-2934-43BD-9541-8C00ED1ECD3EQ27691392-8C81D3E4-97C3-469B-929C-9CBFF38C081DQ28168652-6A4897BD-834D-437E-B682-113EC1A214AE
P2860
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
MRC/BHF Heart Protection Study ...... ised placebo-controlled trial.
@ast
MRC/BHF Heart Protection Study ...... ised placebo-controlled trial.
@en
type
label
MRC/BHF Heart Protection Study ...... ised placebo-controlled trial.
@ast
MRC/BHF Heart Protection Study ...... ised placebo-controlled trial.
@en
prefLabel
MRC/BHF Heart Protection Study ...... ised placebo-controlled trial.
@ast
MRC/BHF Heart Protection Study ...... ised placebo-controlled trial.
@en
P2093
P1433
P1476
MRC/BHF Heart Protection Study ...... ised placebo-controlled trial.
@en
P2093
Heart Protection Study Collaborative Group
Jane Armitage
Peter Sleigh
Richard Peto
Rory Collins
P304
P356
10.1016/S0140-6736(03)13636-7
P407
P50
P577
2003-06-01T00:00:00Z